Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NACompletedINTERVENTIONAL
Enrollment

238

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
GlaucomaOcular Hypertension
Interventions
DRUG

brimonidine tartrate/timolol fixed combination ophthalmic solution

One drop of brimonidine tartrate/timolol fixed combination ophthalmic solution (Combigan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.

DRUG

brimonidine tartrate ophthalmic solution

One drop of brimonidine tartrate ophthalmic solution (Alphagan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.

DRUG

timolol ophthalmic solution

One drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.

OTHER

fixed combination vehicle

Fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.

Trial Locations (1)

Unknown

Guangzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY